In short
A groundbreaking clinical trial is underway to evaluate a novel cancer vaccine called WT1/IL15/IL15Ra mRNA DC. This vaccine is designed to target advanced or refractory solid tumors of the pancreas, esophagus, liver, or ovaries. The study aims to assess the safety, feasibility, and potential effectiveness of this innovative immunotherapy approach in patients who have limited treatment options.
At a glance
- Study Type
- Phase I/II clinical trial
- Treatment
- WT1/IL15/IL15Ra mRNA DC vaccine
- Administration
- Intradermal injection
- Target Conditions
- Advanced or refractory solid tumors of pancreas, esophagus, liver, or ovaries
- Primary Objectives
- Feasibility and safety assessment
- Secondary Objectives
- Clinical efficacy indicators, immunogenicity, quality of life changes
- Key Eligibility Criteria
- Age ≥18, advanced/refractory solid tumors, prior treatment or no standard options available
- Main Exclusion Criteria
- Recent use of investigational agents, active autoimmune disease, pregnancy or breastfeeding
What is WT1/IL15/IL15RA mRNA DC?
WT1/IL15/IL15RA mRNA DC is an experimental cancer vaccine being studied for the treatment of advanced or refractory solid tumors. This innovative therapy belongs to a class of treatments called dendritic cell vaccines, which are designed to stimulate the body's immune system to fight cancer cells.
How Does It Work?
The vaccine is created using a patient's own cells, making it a personalized treatment. Here's a simplified explanation of how it works:
- Doctors collect certain immune cells (monocytes) from the patient's blood through a process called leukapheresis.
- These cells are then transformed into dendritic cells in the laboratory. Dendritic cells are important because they help activate other immune cells to recognize and attack cancer.
- The dendritic cells are then modified with special genetic instructions (mRNA) that tell them to produce three important components:
- WT1 (Wilms' Tumor 1): A protein often found in cancer cells.
- IL15 (Interleukin 15): A substance that helps stimulate immune cells.
- IL15RA (Interleukin 15 Receptor alpha): A component that helps IL15 work more effectively.
- The modified dendritic cells are then given back to the patient through an injection under the skin (intradermal injection).
Once in the body, these specially engineered cells are designed to activate the patient's immune system to recognize and attack cancer cells that have the WT1 protein.
Target Conditions
This experimental treatment is being studied for patients with advanced or refractory solid tumors, specifically in the following organs:
- Pancreas
- Esophagus
- Liver
- Ovaries
The treatment is intended for patients whose cancer has progressed after at least one previous treatment or for whom no standard therapy is available or suitable.
Clinical Trial Details
The WT1/IL15/IL15RA mRNA DC vaccine is currently being studied in a Phase I/II clinical trial. This means it's in the early stages of testing in humans. The main goals of this trial are:
- To evaluate if it's feasible to produce and administer the vaccine.
- To assess the safety of the treatment.
- To look for early signs of effectiveness against the cancer.
- To measure how well the vaccine stimulates the immune system.
- To understand how the treatment affects patients' quality of life.
Eligibility Criteria
Not all patients with the target cancers will be eligible for this trial. Some key eligibility criteria include:
- Age 18 or older
- Confirmed diagnosis of an advanced solid tumor in the pancreas, esophagus, liver, or ovaries
- Cancer that has progressed after at least one previous treatment, or no standard treatment options available
- Reasonable life expectancy of at least 3 months
- Good overall health status (WHO performance status 0-2)
Patients with certain conditions, such as autoimmune diseases or who are pregnant or breastfeeding, may not be eligible for the trial.
Potential Benefits
While it's important to remember that this is an experimental treatment and its effectiveness is not yet proven, the researchers hope to see the following potential benefits:
- Shrinkage or stabilization of tumors
- Longer time before the cancer progresses
- Improved overall survival
- Better quality of life for patients
Safety and Side Effects
As this is a new treatment, all possible side effects are not yet known. The clinical trial will closely monitor patients for any adverse events (side effects) that may occur during and after treatment. The safety of the vaccine is one of the main things being studied in this trial.
It's important for patients to discuss potential risks and benefits with their healthcare team before considering participation in this or any clinical trial.